Macrocure Ltd (NASDAQ:MCUR)
On Friday, Macrocure Ltd (NASDAQ:MCUR)’s shares inclined 84.91% to $1.96.
MCUR has 16.50% institutional ownership while its EPS ratio was -1.87. The company has 16.71 million shares outstanding while market capitalization of the company was $32.75 million. Price to book ratio was 1.05. Stock volatility for the month was booked as 33.56% while for the week was recorded as 19.20%.
The mean estimate for the short term price target for Macrocure Ltd (NASDAQ:MCUR) stands at $1.25 according to 2 Analysts. The higher price target estimate for the stock has been calculated at $1.50 while the lower price target estimate is at $1.00.
Analysts mean recommendation for the stock is 3.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs in the treatment of chronic and other hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs).
Allergan PLC (NYSE:AGN)
Allergan PLC (NYSE:AGN)’s shares gained 3.57% to $312.84.
AGN Its past 5-day performance at 4.41%. So far in 2015, the company has a year-to-date performance of 21.53%. The stock, as of last close, traded 31.56% up from its 52 week low and was -8.19% below its 52 week high. Its latest closing price was 4.67% above the SMA200 while the distance from SMA 50 and SMA 20 was 8.93% and 4.32% respectively.
The mean estimate for the short term price target for Allergan PLC (NYSE:AGN) stands at $363.93 according to 15 Analysts. The higher price target estimate for the stock has been calculated at $400.00 while the lower price target estimate is at $308.00.
Analysts mean recommendation for the stock is 1.60. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution.
Goldman Sachs Group Inc (NYSE:GS)
At the end of Friday’s trade, Goldman Sachs Group Inc (NYSE:GS)‘s shares dipped -0.77% to $191.54.
GS has market capitalization of $81.67 billion. The company offered earning per share of $15.21 while its 426.54 million shares were outstanding. YTD performance of the company was -1.18%. Stock volatility for the week was 1.56% while for the month it was shown at 1.53%.
The mean estimate for the short term price target for Goldman Sachs Group Inc (NYSE:GS) stands at $208.92 according to 24 Analysts. The higher price target estimate for the stock has been calculated at $248.00 while the lower price target estimate is at $156.00.
Analysts mean recommendation for the stock is 2.40. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
The Goldman Sachs Group, Inc. is a bank holding company and a financial holding company. The Company is a global investment banking, securities and investment management company that provides a range of financial services to a diversified client base that include corporations, financial institutions, Governments and individuals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.